Histological evaluations of primary lesions are independently associated with prognosis in patients with gastric cancer who receive neoadjuvant chemotherapy

Tahara,Tomomitsu; Shibata,Tomoyuki; Okubo,Masaaki; Yoshida,Dai; Kawamura,Tomohiko; Horiguchi,Noriyuki; Ishizuka,Takamitsu; Nagasaka,Mitsuo; Nakagawa,Yoshihito; Ohmiya,Naoki

doi:10.3892/ol.2017.6040

Histological evaluations of primary lesions are independently associated with prognosis in patients with gastric cancer who receive neoadjuvant chemotherapy

Authors:
- Tomomitsu Tahara
- Tomoyuki Shibata
- Masaaki Okubo
- Dai Yoshida
- Tomohiko Kawamura
- Noriyuki Horiguchi
- Takamitsu Ishizuka
- Mitsuo Nagasaka
- Yoshihito Nakagawa
- Naoki Ohmiya
View Affiliations

Affiliations: Department of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Aichi 470‑1192, Japan
Published online on: April 18, 2017 https://doi.org/10.3892/ol.2017.6040
Pages: 4892-4896

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neoadjuvant chemotherapy may improve outcomes for patients with locally advanced gastric cancer (GC). To explore useful predictive factors for the response of advanced GC to neoadjuvant chemotherapy, tumor responses were assessed using computed tomography (CT) with histological based criteria. A total of 78 patients with advanced GC undergoing neoadjuvant chemotherapy were included. CT‑based response assessment was performed following 2 courses of treatment. Histological evaluation of resected specimens was also performed according to the Japanese classification of gastric carcinoma. Grade 1b, 2 and 3 (viable tumor cells remaining in <2/3 of the tumorous area) were defined as histological responders. The results were associated with overall survival (OS) and progression‑free survival (PFS). The majority of the cases underwent tegafur/gimeracil/oteracil based preoperative chemotherapy as the first line of treatment (n=76, 96%). A total of 25 (32%) and 29 (37%) cases were considered to be CT and histological responders, respectively. CT-based evaluation was not associated with OS or PFS, while histological evaluation was significantly associated with OS and PFS. Histological based evaluation was not associated with CT and GI X‑ray or endoscopy‑based evaluation of primary lesions. Multivariate survival analysis using Cox's regression model demonstrated that histological non‑response was an independent prognostic factor for predicting worse OS. Histological-based evaluation of primary lesions was independently associated with prognosis in patients with GC who underwent neoadjuvant chemotherapy.

View Figures

View References

1	Ferlay J, Bray F, Parkin DM and Pisani P: Gobocan 2000: Cancer incidence and mortality worldwide (IARC Cancer Bases No. 5). Lyon: IARC Press; 2001
2	Lau M, Le A and El-Serag HB: Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: Secular trends in incidence and survival. Am J Gastroenterol. 101:2485–2492. 2006. View Article : Google Scholar : PubMed/NCBI
3	Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, et al: Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 16:1–27. 2013. View Article : Google Scholar : PubMed/NCBI
4	Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
5	Yamaguchi K, Sawaki A, Doi T, Satoh T, Yamada Y, Omuro Y, Nishina T, Boku N, Chin K, Hamamoto Y, et al: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: Subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer. 16:175–182. 2013. View Article : Google Scholar : PubMed/NCBI
6	Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, Takagi S, Azuma M, Ae T, Ishido K, et al: A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. 69:407–413. 2012. View Article : Google Scholar : PubMed/NCBI
7	Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 9:215–21. 2008. View Article : Google Scholar : PubMed/NCBI
8	Okines AF, Norman AR, McCloud P, Kang YK and Cunningham D: Meta-analysis of the REAL-2 and ML17032 trials: Evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 20:1529–1534. 2009. View Article : Google Scholar : PubMed/NCBI
9	Hamaguchi T, Shirao K, Ohtsu A, Hyodo I, Arai Y, Takiuchi H, Fujii H, Yoshida M, Saito H, Denda T, et al: A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: A report from the Gastrointestinal oncology group of the Japan clinical oncology group (JCOG0109-DI Trial). Gastric Cancer. 14:226–233. 2011. View Article : Google Scholar : PubMed/NCBI
10	Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
11	Kodera Y, Ishiyama A, Yoshikawa T, Kinoshita T, Ito S, Yokoyama H, Mochizuki Y, Ito H, Tsuburaya A, Sakamoto J, et al: A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer. 13:197–203. 2010. View Article : Google Scholar : PubMed/NCBI
12	Tsuburaya A, Nagata N, Cho H, Hirabayashi N, Kobayashi M, Kojima H, Munakata Y, Fukushima R, Kameda Y, Shimoda T, et al: Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol. 71:1309–1314. 2013. View Article : Google Scholar : PubMed/NCBI
13	Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, et al: A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: Nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol. 71:789–797. 2013. View Article : Google Scholar : PubMed/NCBI
14	Yoshikawa T, Rino Y, Yukawa N, Oshima T, Tsuburaya A and Masuda M: Neoadjuvant chemotherapy for gastric cancer in Japan: A standing position by comparing with adjuvant chemotherapy. Surg Today. 44:11–21. 2014. View Article : Google Scholar : PubMed/NCBI
15	Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M and Siewert JR: Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 24:4692–46988. 2006. View Article : Google Scholar : PubMed/NCBI
16	Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschläger G, Busch R, Siewert JR, Schwaiger M and Fink U: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 19:3058–3065. 2001. View Article : Google Scholar : PubMed/NCBI
17	Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, et al: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol. 8:797–805. 2007. View Article : Google Scholar : PubMed/NCBI
18	Japanese Gastric Cancer Association, . Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kurokawa Y, Shibata T, Sasako M, Sano T, Tsuburaya A, Iwasaki Y and Fukuda H: Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). Gastric Cancer. 17:514–521. 2014. View Article : Google Scholar : PubMed/NCBI
20	Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR and Höfler H: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 98:1521–1530. 2003. View Article : Google Scholar : PubMed/NCBI
21	Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K, et al: Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer. 17:478–488. 2014. View Article : Google Scholar : PubMed/NCBI
22	Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI
23	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
24	Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, Lordick F, Link T, Schwaiger M, et al: Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial. J Clin Oncol. 21:4604–4610. 2003. View Article : Google Scholar : PubMed/NCBI